The FDA has approved a fixed-dose triple combination therapy for the maintenance treatment of asthma in adults and children aged 12 years and older, according to a press release from manufacturer ...
The FDA approved Breztri Aerosphere, a single-inhaler triple therapy, as a maintenance treatment for patients aged at least ...
Incorrect inhaler technique reduces drug delivery, worsens asthma control, and increases attacks - proper use, training, and ...
After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has ...
Breztri Aerosphere is a single-inhaler fixed-dose triple therapy that combines budesonide, glycopyrrolate, and formoterol fumarate.
The FDA has approved AstraZeneca’s Breztri Aerosphere as the first maintenance triple therapy for asthma in patients aged 12 and older. The inhaler combines an inhaled corticosteroid, a long-acting ...
New reliever therapy reduced airway inflammation in adults with asthma using maintenance inhaled corticosteroids. Read more.
A monthly injection could enable severe asthma patients to stop taking daily steroid tablets without affecting their symptoms, a new trial has found. The drug, Tezepelumab (also known as Tezspir and ...
According to a study released late Wednesday in Lancet Respiratory Medicine, monthly injections of Tezepelumab helped 90% of patients with severe asthma reduce their dosage of corticosteroids. The ...
The FDA has granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe eosinophilic asthma.
Timing transforms outcomes For people living with severe asthma, outcomes are not determined only by what treatment they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results